Sponsor
Maxine Dexter
Representative · D-OR
Representative · D-OR
The bill increases consumer transparency and FDA oversight of dietary supplements through a public product‑listing database and dedicated funding, while imposing new compliance burdens and some disclosure and fiscal costs on manufacturers and taxpayers.
Consumers gain a searchable federal database to look up dietary supplements by product listing number and label, improving transparency and making it easier to verify products they buy.
Manufacturers must provide label and ingredient details (including amount per serving), which helps detect misleading claims or unsafe ingredients and supports better oversight.
Establishing unique product listing numbers and a reservation process creates clearer product identifiers that can streamline recalls, enforcement actions, and supply‑chain tracking.
Small manufacturers and distributors face new compliance costs and administrative burdens to prepare and submit listings and respond to five‑day information requests.
Products that fail to list or update required information are deemed misbranded, exposing firms to enforcement actions, removal from the market, and legal risk for noncompliance.
The public database may disclose labels, formulations, or other sensitive business information (only limited FOIA exemptions apply), risking competitive harm to firms.
Based on analysis of 2 sections of legislative text.
Requires mandatory federal listing and a public database for all dietary supplements, assigns product listing numbers, and funds FDA implementation.
Official title: To improve transparency and the availability of information regarding dietary supplements by amending the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary supplements to list dietary supplements with the Food and Drug Administration.
Introduced April 20, 2026 by Maxine Dexter · Last progress April 20, 2026
Creates a new federal requirement that all dietary supplements marketed in the United States be listed in a centralized, searchable database and assigned a product listing number. Responsible persons (or U.S. agents for foreign firms) must submit product and facility information electronically, respond to FDA requests for additional location/source details within five days, and may not market supplements that fail to meet listing or information requests; limited proprietary information is protected. The FDA must establish the public database and issue listing numbers within two years and receives specified funding for implementation and staffing through FY2030.